利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

131 条记录 (耗时 0.03 秒)

    METHODS FOR PREVENTION AND TREATMENT OF CARDIOMETABOLIC SYNDROME AND COMPOSITIONS USED THEREIN
    8.
    发明申请
    METHODS FOR PREVENTION AND TREATMENT OF CARDIOMETABOLIC SYNDROME AND COMPOSITIONS USED THEREIN 审中-公开
    预防和治疗糖尿病综合征及其使用的组合物的方法

    公开(公告)号：US20160287530A1

    公开(公告)日：2016-10-06

    申请号：US15088662

    申请日：2016-04-01

    申请人： OmniActive Health Technologies Limited

    发明人： Jayant DESHPANDE ,  Abhijit BHATTACHARYA ,  Vijaya JUTURU

    IPC分类号： A61K31/047 ,  G01N33/92

    CPC分类号： A61K31/047 ,  A61K31/045 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/485 ,  G01N2333/70525 ,  G01N2333/90245 ,  G01N2333/90254 ,  G01N2333/90283 ,  G01N2333/908 ,  G01N2800/04 ,  G01N2800/32

    摘要： Beta-cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors, in a subject, in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta-cryptoxanthin composition to assess the condition of an organ. Compositions and methods herein can effectively reduce risk factors of cardiometabolic syndrome, such as hyperlipidemia, insulin resistance, obesity, diabetes, atherosclerosis and/or related cardiovascular disorders. Beta-cryptoxanthin compositions and methods herein can reduce body weight, body fat, glucose levels, and free fatty acids, when administered in effective amounts. The compositions and methods herein can also reduce oxidative stress on organs such as the eye and liver and/or reduce inflammatory and/or oxidative markers, when administered to subjects in need thereof.

    摘要翻译： β-保护黄质组合物和方法描述用于在有需要的受试者中管理心脏代谢综合征和相关的危险因素。 本文的方法旨在鉴定具有发展心脏代谢综合征和施用β-隐黄质组成以评估器官状况的风险的受试者。 本文的组合物和方法可有效降低心脏代谢综合征的危险因素，如高脂血症，胰岛素抵抗，肥胖，糖尿病，动脉粥样硬化和/或相关心血管疾病。 当以有效量施用时，本发明的β-隐黄质组合物和方法可以降低体重，体脂肪，葡萄糖水平和游离脂肪酸。 当给予有需要的受试者时，本文的组合物和方法还可以减少器官如眼睛和肝脏上的氧化应激和/或减少炎症和/或氧化标志物。

    SYNTHETIC MICROFLUIDIC SYSTEMS FOR WOUND HEALING
    10.
    发明申请
    SYNTHETIC MICROFLUIDIC SYSTEMS FOR WOUND HEALING 有权
    合成微血管系统治疗伤口愈合

    公开(公告)号：US20160161469A1

    公开(公告)日：2016-06-09

    申请号：US15041963

    申请日：2016-02-11

    申请人： CFD Research Corporation

    发明人： Balabhaskar Prabhakarpandian ,  Kapil Pant

    IPC分类号： G01N33/50 ,  G01N33/86

    CPC分类号： G01N33/5029 ,  B01L3/5027 ,  G01N33/5005 ,  G01N33/5011 ,  G01N33/5061 ,  G01N33/5088 ,  G01N33/86 ,  G01N2333/4703 ,  G01N2333/70525

    摘要： A method of assaying wound healing can include: growing cells on the matrix in the first flow channel; introducing an agent that removes the matrix from the junction; introducing a matrix material into the second flow channel so as to form the second matrix in the second flow channel and junction; and detecting cellular migration into the junction onto the second matrix. The agent that removes the matrix can include a biomolecule or chemical agent. The method can include removing cells in the matrix in the junction before introducing the matrix material into the second flow channel. A bioactive agent can be introduced into the junction to determine if it modulates cellular migration and/or clot formation into the intersection openings of tissue and vascular channels.

    摘要翻译： 测定伤口愈合的方法可以包括：在第一流动通道中在基质上生长细胞; 引入从接合处去除基质的试剂; 将基质材料引入到第二流动通道中，以便在第二流动通道和结中形成第二基质; 并检测细胞迁移到第二基质上的结。 去除基质的试剂可以包括生物分子或化学试剂。 该方法可以包括在将基质材料引入第二流动通道之前去除接合中的基体中的细胞。 可以将生物活性剂引入接头以确定其是否调节细胞迁移和/或凝块形成到组织和血管通道的交叉开口中。